Polyrizon Ltd. is an Israeli biotechnology company developing hydrogel-based medical devices formulated as nasal sprays. The company's proprietary technology platform focuses on two primary applications: barrier formulations that block allergen particulates and viruses from the nasal cavity, and delivery systems for administering active pharmaceutical ingredients through nasal spray. Its product pipeline includes PL-14 for allergic rhinitis, PL-15 for COVID-19 prevention, and PL-16 for influenza prevention.
The company operates with a minimal headcount of two full-time employees and is incorporated in Israel, with headquarters in Ra'anana. Polyrizon was founded in 2005 and is listed on Nasdaq. The company's revenue streams and commercialization status are not publicly detailed, and its market presence remains early-stage relative to established medical device manufacturers.
No 10-K filings found.